Takeda Pharmaceutical Co Ltd ADR TAK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States
Takeda Pharmaceutical Raises Annual Guidance
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Trading Information
- Previous Close Price
- $20.84
- Day Range
- $21.08–21.30
- 52-Week Range
- $13.99–21.72
- Bid/Ask
- $21.18 / $21.19
- Shares Outstanding
- 3.19B
- Market Cap
- $67.72B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 42.33
- Price/Sales
- 2.21
- Dividend Yield (Trailing)
- 3.03%
- Dividend Yield (Forward)
- 2.96%
- Dividend Payment Schedule
- Jul, Dec
- Total Yield
- 3.03%
Company Profile
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 47,029
- Website
- https://www.takeda.com
Competitors
Valuation
Metric | TAK | 4568 | 4519 |
|---|---|---|---|
Price/Earnings (Normalized) | 42.33 | 16.35 | 22.95 |
Price/Book Value | 1.41 | 2.96 | 5.63 |
Price/Sales | 2.21 | 2.26 | 8.32 |
Price/Cash Flow | 14.79 | 43.14 | 21.52 |
Price/Earnings
TAK
4568
4519
Financial Strength
Metric | TAK | 4568 | 4519 |
|---|---|---|---|
Quick Ratio | 0.52 | 1.62 | 3.43 |
Current Ratio | 1.15 | 2.70 | 4.35 |
Interest Coverage | 1.70 | 12.11 | — |
Quick Ratio
TAK
4568
4519
Profitability
Metric | TAK | 4568 | 4519 |
|---|---|---|---|
Return on Assets (Normalized) | 5.67% | 7.41% | 21.45% |
Return on Equity (Normalized) | 11.63% | 17.26% | 25.34% |
Return on Invested Capital (Normalized) | 7.93% | 13.58% | 25.34% |
Return on Assets
TAK
4568
4519
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|MGRq$Q?v | LOCK|Q&^^ | $74B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|Mh%J%&$ | LOCK|??s!c | $50B | |||
| Haleon PLC ADR HLN | LOCK|FPXlFF | LOCK|?^ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|$H$@pG># | LOCK|gQ | $34B | |||
| Viatris Inc VTRS | LOCK|#Lqr#H | LOCK|WW$ | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|R& | LOCK|Fh | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|ZmV!Kd& | LOCK|lD | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|yR<Y!#> | LOCK|W^ | $5B | |||
| Perrigo Co PLC PRGO | LOCK|J!dvNFL | LOCK|QY | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|rfFcKg< | LOCK|dNXY^ | $2B |
United States